Literature DB >> 21351324

Neuropeptide Y receptors: ligand binding and trafficking suggest novel approaches in drug development.

Cornelia Walther1, Karin Mörl, Annette G Beck-Sickinger.   

Abstract

NPY, PYY and PP constitute the so-called NPY hormone family, which exert its biological functions in humans through YRs (Y₁, Y₂, Y₄ and Y₅). Systematic modulation of YR function became important as this multireceptor/multiligand system is known to mediate various essential physiological key functions and is involved in a variety of major human diseases such as epilepsy, obesity and cancer. As several YRs have been found to be overexpressed on different types of malignant tumors they emerge as promising target in modern drug development. Here, we summarize the current understanding of YRs function and the molecular mechanisms of ligand binding and trafficking. We further address recent advances in YR-based drug design, the development of promising future drug candidates and novel approaches in YR-targeted tumor diagnostics and therapy opportunities.
Copyright © 2011 European Peptide Society and John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21351324     DOI: 10.1002/psc.1357

Source DB:  PubMed          Journal:  J Pept Sci        ISSN: 1075-2617            Impact factor:   1.905


  20 in total

1.  Mutations in arrestin-3 differentially affect binding to neuropeptide Y receptor subtypes.

Authors:  Luis E Gimenez; Stefanie Babilon; Lizzy Wanka; Annette G Beck-Sickinger; Vsevolod V Gurevich
Journal:  Cell Signal       Date:  2014-03-29       Impact factor: 4.315

2.  Single Cell Peptide Heterogeneity of Rat Islets of Langerhans.

Authors:  Erik T Jansson; Troy J Comi; Stanislav S Rubakhin; Jonathan V Sweedler
Journal:  ACS Chem Biol       Date:  2016-07-29       Impact factor: 5.100

3.  Neuropeptide Y as a Biomarker and Therapeutic Target for Neuroblastoma.

Authors:  Susana Galli; Arlene Naranjo; Collin Van Ryn; Jason U Tilan; Emily Trinh; Chao Yang; Jessica Tsuei; Sung-Hyeok Hong; Hongkun Wang; Ewa Izycka-Swieszewska; Yi-Chien Lee; Olga C Rodriguez; Chris Albanese; Joanna Kitlinska
Journal:  Am J Pathol       Date:  2016-10-12       Impact factor: 4.307

Review 4.  Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.

Authors:  Robert E Steinert; Christine Feinle-Bisset; Lori Asarian; Michael Horowitz; Christoph Beglinger; Nori Geary
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

5.  Discovery of a Novel Class of Bicyclo[3.1.0]hexanylpiperazines as Noncompetitive Neuropeptide Y Y1 Antagonists.

Authors:  Shuanghua Hu; Yazhong Huang; Milind Deshpande; Guanglin Luo; Marc A Bruce; Ling Chen; Gail Mattson; Lawrence G Iben; Jie Zhang; John W Russell; Wendy J Clarke; John B Hogan; Astrid Ortiz; Oliver Flint; Andrew Henwood; Qi Gao; Ildiko Antal-Zimanyi; Graham S Poindexter
Journal:  ACS Med Chem Lett       Date:  2012-01-04       Impact factor: 4.345

6.  Increases in PYY and uncoupling of bone turnover are associated with loss of bone mass after gastric bypass surgery.

Authors:  Tiffany Y Kim; Dolores M Shoback; Dennis M Black; Stanley J Rogers; Lygia Stewart; Jonathan T Carter; Andrew M Posselt; Nicole J King; Anne L Schafer
Journal:  Bone       Date:  2019-11-02       Impact factor: 4.398

7.  Binding of Natural Peptide Ligands to the Neuropeptide Y5 Receptor.

Authors:  Sarina Rudolf; Kerstin Kaempf; Oanh Vu; Jens Meiler; Annette G Beck-Sickinger; Irene Coin
Journal:  Angew Chem Int Ed Engl       Date:  2021-12-16       Impact factor: 15.336

Review 8.  Emerging neuropeptide targets in inflammation: NPY and VIP.

Authors:  Bindu Chandrasekharan; Behtash Ghazi Nezami; Shanthi Srinivasan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-03-28       Impact factor: 4.052

9.  PYY(3-36) into the arcuate nucleus inhibits food deprivation-induced increases in food hoarding and intake.

Authors:  Brett J W Teubner; Timothy J Bartness
Journal:  Peptides       Date:  2013-06-29       Impact factor: 3.750

10.  Characterization of transcriptional changes in ERG rearrangement-positive prostate cancer identifies the regulation of metabolic sensors such as neuropeptide Y.

Authors:  Petra Massoner; Karl G Kugler; Karin Unterberger; Ruprecht Kuner; Laurin A J Mueller; Maria Fälth; Georg Schäfer; Christof Seifarth; Simone Ecker; Irmgard Verdorfer; Armin Graber; Holger Sültmann; Helmut Klocker
Journal:  PLoS One       Date:  2013-02-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.